De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Puma Biotechnology Beheer
Beheer criteriumcontroles 3/4
De CEO Puma Biotechnology's is Alan Auerbach, benoemd in Sep2010, heeft een ambtstermijn van 14.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.94M, bestaande uit 29.8% salaris en 70.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 14.05% van de aandelen van het bedrijf, ter waarde $ 17.57M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.3 jaar en 7.9 jaar.
Belangrijke informatie
Alan Auerbach
Algemeen directeur
US$2.9m
Totale compensatie
| Percentage CEO-salaris | 29.8% |
| Dienstverband CEO | 14.1yrs |
| Eigendom CEO | 14.1% |
| Management gemiddelde ambtstermijn | 6.3yrs |
| Gemiddelde ambtstermijn bestuur | 7.9yrs |
Recente managementupdates
Recent updates
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Aug 04Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
Jun 04Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | US$15m |
| Dec 31 2023 | US$3m | US$878k | US$22m |
| Sep 30 2023 | n/a | n/a | US$4m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | US$5m |
| Dec 31 2022 | US$3m | US$852k | US$2k |
| Sep 30 2022 | n/a | n/a | US$10m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$18m | US$827k | -US$29m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$27m |
| Dec 31 2020 | US$4m | US$834k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$780k | -US$76m |
| Sep 30 2019 | n/a | n/a | -US$95m |
| Jun 30 2019 | n/a | n/a | -US$92m |
| Mar 31 2019 | n/a | n/a | -US$99m |
| Dec 31 2018 | US$6m | US$757k | -US$114m |
| Sep 30 2018 | n/a | n/a | -US$147m |
| Jun 30 2018 | n/a | n/a | -US$210m |
| Mar 31 2018 | n/a | n/a | -US$243m |
| Dec 31 2017 | US$3m | US$733k | -US$292m |
Compensatie versus markt: De totale vergoeding ($USD 2.94M ) Alan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).
Compensatie versus inkomsten: De vergoeding van Alan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Alan Auerbach (54 yo)
14.1yrs
Tenure
US$2,944,748
Compensatie
Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman since October 4, 2011 and serves as its Chief Executive Officer, President and Secretary since September...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 14.1yrs | US$2.94m | 14.05% $ 17.6m | |
| CFO & Principal Accounting Officer | 5.9yrs | US$1.23m | 0.24% $ 294.3k | |
| Chief Regulatory Affairs | 6.8yrs | US$1.02m | 0.19% $ 236.6k | |
| Chief Commercial Officer | 4.6yrs | US$1.38m | 0.17% $ 207.4k | |
| Senior Director of Investor Relations | 12.9yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development | less than a year | geen gegevens | geen gegevens |
6.3yrs
Gemiddelde duur
56.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PBYI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 13yrs | US$2.94m | 14.05% $ 17.6m | |
| Lead Independent Director | 12.5yrs | US$172.27k | 0.043% $ 54.4k | |
| Independent Director | 6.7yrs | US$162.90k | 0.041% $ 51.0k | |
| Independent Director | 11yrs | US$172.27k | 0.0018% $ 2.3k | |
| Independent Director | 2.3yrs | US$152.27k | 0.055% $ 68.9k | |
| Independent Director | 9.2yrs | US$164.77k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$154.77k | 0.067% $ 84.1k | |
| Independent Director | 4.3yrs | US$161.65k | 0.10% $ 125.1k |
7.9yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PBYI wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).